Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Valorization of Olive Mill Wastewater by Membrane Processes to Recover Natural Antioxidant Compounds for Cosmeceutical and Nutraceutical Applications or Functional Foods.

Alfano A, Corsuto L, Finamore R, Savarese M, Ferrara F, Falco S, Santabarbara G, De Rosa M, Schiraldi C.

Antioxidants (Basel). 2018 May 23;7(6). pii: E72. doi: 10.3390/antiox7060072.

2.

Selumetinib for the treatment of non-small cell lung cancer.

Casaluce F, Sgambato A, Maione P, Sacco PC, Santabarbara G, Gridelli C.

Expert Opin Investig Drugs. 2017 Aug;26(8):973-984. doi: 10.1080/13543784.2017.1351543. Epub 2017 Jul 12. Review.

PMID:
28675058
3.

Complete response to capecitabine in a frail, elderly patient with metastatic colorectal cancer: A case report.

Fasano M, Fabozzi A, Giordano G, Venturini F, Aurilio G, Cantile F, Fabozzi T, Ricci V, Santabarbara G, Morgillo F, Ciardiello F, De Vita F.

Oncol Lett. 2017 Feb;13(2):979-983. doi: 10.3892/ol.2016.5523. Epub 2016 Dec 20.

4.

The safety of second-line treatment options for non-small cell lung cancer.

Rossi A, Maione P, Santabarbara G, Sacco PC, Casaluce F, Sgambato A, Barzelloni ML, Palazzolo G, Gridelli C.

Expert Opin Drug Saf. 2017 Apr;16(4):471-479. doi: 10.1080/14740338.2017.1297795. Epub 2017 Mar 1. Review.

PMID:
28276858
5.

Developments in pharmacotherapy for treating metastatic non-small cell lung cancer.

Rossi A, Sacco PC, Santabarbara G, Sgambato A, Casaluce F, Palazzolo G, Maione P, Gridelli C.

Expert Opin Pharmacother. 2017 Feb;18(2):151-163. doi: 10.1080/14656566.2017.1280460. Epub 2017 Jan 20. Review.

PMID:
28067062
6.

The Role of the Antiangiogenetic Ramucirumab in the Treatment of Advanced Non Small Cell Lung Cancer.

Maione P, Sgambato A, Casaluce F, Sacco PC, Santabarbara G, Rossi A, Gridelli C.

Curr Med Chem. 2017;24(1):3-13. doi: 10.2174/0929867324666161118125103. Review.

PMID:
27855622
7.

The role of pembrolizumab in the treatment of advanced non-small cell lung cancer.

Santabarbara G, Maione P, Rossi A, Palazzolo G, Gridelli C.

Ann Transl Med. 2016 Jun;4(11):215. doi: 10.21037/atm.2016.05.64. Review.

8.

Overcoming Resistance to EGFR Inhibitors in NSCLC.

Maione P, Sacco PC, Casaluce F, Sgambato A, Santabarbara G, Rossi A, Gridelli C.

Rev Recent Clin Trials. 2016;11(2):99-105. Review.

PMID:
27028971
9.

Optimal drugs for second-line treatment of patients with small-cell lung cancer.

Rossi A, Sacco PC, Sgambato A, Casaluce F, Santabarbara G, Palazzolo G, Maione P, Gridelli C.

Expert Opin Pharmacother. 2016;17(7):969-76. doi: 10.1517/14656566.2016.1154539. Epub 2016 Feb 29. Review.

PMID:
26878692
10.

Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer.

Rossi E, Sgambato A, De Chiara G, Casaluce F, Losanno T, Sacco PC, Santabarbara G, Gridelli C.

Expert Rev Clin Pharmacol. 2016;9(3):419-28. doi: 10.1586/17512433.2016.1133289. Epub 2016 Feb 6. Review.

PMID:
26681547
11.

Pharmacotherapeutic options for treating adverse effects of Cisplatin chemotherapy.

Santabarbara G, Maione P, Rossi A, Gridelli C.

Expert Opin Pharmacother. 2016;17(4):561-70. doi: 10.1517/14656566.2016.1122757. Epub 2015 Dec 17.

PMID:
26581586
12.

Current status of targeted therapies in advanced gastric cancer.

De Vita F, Giuliani F, Silvestris N, Rossetti S, Pizzolorusso A, Santabarbara G, Galizia G, Colucci G, Ciardiello F, Orditura M.

Expert Opin Ther Targets. 2012 Apr;16 Suppl 2:S29-34. doi: 10.1517/14728222.2011.652616. Epub 2012 Mar 23. Review.

PMID:
22443228

Supplemental Content

Loading ...
Support Center